SWM
NKTR icon

Sugarloaf Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Sugarloaf Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7
Closed -$2K – 787
2021
Q2 		$2K Hold
7
– – ﹤0.01% 683
2021
Q1 		$2 Buy
+7
New +$2.18K ﹤0.01% 682

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sugarloaf Wealth Management's NKTR Position: Q3 2021 in Review

Sugarloaf Wealth Management sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 7 shares — an estimated $2K sold.

Sugarloaf Wealth Management first reported a position in NKTR in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Sugarloaf Wealth Management reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 7 Nektar Therapeutics shares in Q3 2021, an estimated $2K.
  • Sugarloaf Wealth Management first reported a position in Nektar Therapeutics in Q1 2021 and held it in 2 quarters.
  • Sugarloaf Wealth Management's Nektar Therapeutics position peaked at $2K in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2021, filed 20 Oct 2021.